No Data
Reported Earlier, Subaru Selects Onsemi Hyperlux Sensors To Enhance AI-Integrated EyeSight Driver Assistance System
The rebound also functions with the 200-day line as a support.
The Nikkei average rebounded. It closed the trading at 38,414.43 yen, up 193.58 yen (approximately 1.8 billion shares in volume), following the trend in the US market. It started with a rebound, recovering the milestone of 38,500 yen just after the opening. However, active buying was limited, and there were scenes where the price increase narrowed to 38,246.36 yen in the mid-morning session. Subsequently, although the market development was characterized by a stalemate, there were also moments in the afternoon session when the price briefly exceeded the high of 38,560.10 yen set in the morning.
Nikkei Rises 0.5%, Led by Banks, Nonferrous Metals-Related Names -- Market Talk
The Nikkei average has rebounded and is fluctuating slightly while waiting for nvidia's earnings report.
On the 18th, the USA market was mixed. The Dow Jones Industrial Average closed the trading session at 43,389.60, down 55.39 points, while the NASDAQ ended at 18,791.81, up 111.69 points. With limited news at the opening, the market was mixed. The unexpected improvement in the November NAHB Housing Market Index and strong growth expectations provided support, but the Dow was pressured by profit-taking sales and traded weakly throughout the day. The NASDAQ was supported by the rise of electric car maker Tesla, a decline in long-term interest rates, and expectations for the earnings of semiconductor company NVIDIA.
Sapporo Holdings hits a new high.
The stocks that reached new highs on the main board are Shikoku Electric Engineering <1939> and Sankei Industry <1961> with 34 stocks. The stocks that reached new lows on the main board are Ito En <2593> and Nexon <3659> with 15 stocks. "Main Board" "Tokyo Standard" "Tokyo Growth" New Highs New Lows New Highs New Lows New Highs New Lows 11/19 34 15 23 16 12 11 11/18 28 47 24 31 13 16 11/15 37 41 26 35 11 28 11/14 14 14 42 12 78 1.
Chordia---a biotech venture advancing the development of anticancer drugs that could become block inc.
Chordia Therapeutics <190A> is a biotech venture founded by drug discovery researchers who spun out from takeda pharmaceuticals sp adr <4502>, specializing in the development of low molecular weight anti-cancer drugs. The core business ranges from exploratory research to clinical research, and domestically, it conducts manufacturing and sales on its own through a partnership strategy, aiming for early monetization by licensing out overseas. It was listed on the Tokyo Stock Exchange Growth Market in June 2024.